Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Grand Brilliance Group Holdings Net Margin %?
Grand Brilliance Group HoldingsHKSE:08372 66 Net Margin % is 9.06% as of Mar. 2026, which is 9% below its 10-year median of 9.94. GuruFocus rates HKSE:08372 with a GF Score™ of 66/100 and a GF Value™ of HK$0.12 (Fairly Valued). The stock has 5 warning signs investors should review. Among 119 Medical Distribution companies, Grand Brilliance Group Holdings ranks better than 88.24% on this metric.
Grand Brilliance Group Holdings (HKSE:08372) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Grand Brilliance Group Holdings Net Margin % Related Terms
Grand Brilliance Group Holdings Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grand Brilliance Group Holdings Net Margin % Chart
HKSE:08372 vs MCK, COR, CAH: Net Margin % Comparison
For the Medical Distribution subindustry, Grand Brilliance Group Holdings's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Grand Brilliance Group Holdings Net Margin % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Grand Brilliance Group Holdings's Net Margin % distribution charts can be found below:
* The bar in red indicates where Grand Brilliance Group Holdings's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Grand Brilliance Group Holdings (HKSE:08372) has a Net Margin % of 9.06% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Grand Brilliance Group Holdings and its competitors. This is near median its historical median of 9.94. According to the industry distribution chart, Grand Brilliance Group Holdings ranks #14 out of 119 companies in the Medical Distribution industry, placing it in the top 11.8%.
Is Grand Brilliance Group Holdings' Net Margin % too high?
Grand Brilliance Group Holdings' current Net Margin % of 9.06% is near median its 10-year median of 9.94. The Medical Distribution industry median Net Margin % is 1.47. Grand Brilliance Group Holdings' value of 9.06% is 516.3% above this industry median. Based on the distribution chart, Grand Brilliance Group Holdings ranks #14 out of 119 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Grand Brilliance Group Holdings has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Grand Brilliance Group Holdings' Net Margin % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Grand Brilliance Group Holdings ranks #14 out of 119 companies for Net Margin %. This places Grand Brilliance Group Holdings in the top 12% of its industry — outperforming the majority of peers. The industry median Net Margin % is 1.47. Grand Brilliance Group Holdings' value of 9.06% is 516.3% above this benchmark. While the company's 10-year median is 9.94 vs. the industry median of 1.47, Grand Brilliance Group Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Distribution company?
The median Net Margin % among Medical Distribution companies is 1.47, based on 119 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grand Brilliance Group Holdings's current Net Margin % of 9.06% is 516.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Grand Brilliance Group Holdings and its competitors. For the Medical Distribution industry, the median Net Margin % is 1.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grand Brilliance Group Holdings's current Net Margin % is 9.06%, which is near median its own 10-year median of 9.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grand Brilliance Group Holdings stock overvalued right now?
Based on GuruFocus' analysis, Grand Brilliance Group Holdings (HKSE:08372) is currently considered Fairly Valued. The stock's GF Value™ is HK$0.12, compared to a current price of HK$0.13 — trading 5.8% above its estimated fair value. The current Net Margin % is 9.06%, which is near median its 10-year median of 9.94 and 516.3% above the Medical Distribution industry median of 1.47. Grand Brilliance Group Holdings' overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Grand Brilliance Group Holdings (HKSE:08372), the current Net Margin % is 9.06% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Grand Brilliance Group Holdings (HKSE:08372) Overvalued in 2026?
Based on GuruFocus' analysis, Grand Brilliance Group Holdings stock appears to be overvalued.
The current stock price of HK$0.13 is trading 5.8% above its estimated GF Value™ of HK$0.12.
GuruFocus considers Grand Brilliance Group Holdings to be Fairly Valued.
Key valuation signals for HKSE:08372:
Net Margin %: 9.06% (near median its 10-year median of 9.94)
GF Value™: HK$0.12 vs. price of HK$0.13 (5.8% above fair value)
Industry Position: 516.3% above the Medical Distribution median (#14 of 119)
No single metric tells the full story. See the HKSE:08372 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Grand Brilliance Group Holdings Ltd is an investment holding. The company is engaged in the business of medical device distribution. The company also provides one-stop medical device solutions, including market trend analysis, sourcing of medical devices, after-sale services, technical support, and training services, medical device leasing services, and quality assurance. Geographically, the company derives revenue from Hong Kong. It serves private hospitals, public hospitals, private clinics, non-profit organizations, universities, and individual end-users in Hong Kong.
66GF Score
Get the complete analysis for HKSE:08372
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08372 has been successfully added to your 
